Using HRAs Employers that want to avoid covering GLP-1s for weight loss in their general health plans could provide a health reimbursement account (HRA), using pre-tax dollars, to cover a portion of the cost of these medications
It uses the same active molecule as injectable tirzepatide, taken by mouth instead of by injection, under provider supervision
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease
Abstract Tirzepatide has been approved for the management of obesity, obstructive sleep apnea, and type 2 diabetes mellitus
Statistical analysis was performed using STATA statistical software (version 18, StataCorp LLC)
New anti-obesity medications (AOMs), including semaglutide and tirzepatide, offer promising options for managing obesity and may be potential treatment options for obstructive sleep apnea